Dr. Jonathan Kolitz, MD
Hematology & Oncology (Hematology & Oncology Physician)
The Monter Cancer Center, 450 Lakeville Road
Lake Success, NY 11042
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 380
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: Yale University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 144370
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
- Long Island Jewish Medical Center New Hyde PArk, NY
Medical groups
- North Shore Health System Medical Faculty Group Practice Inc (164 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 380
- Services billed
- 1,620
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 659 | 247 |
| Established patient office or other outpatient visit, 20-29 minutes | 314 | 190 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 151 | 29 |
| Established patient office or other outpatient visit, 40-54 minutes | 73 | 60 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 54 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levofloxacin Other prescribers in Lake Success, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $165,028 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination with Anti-lymphoma A…
E.r. Squibb & Sons, L.l.c. - A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Genmab A/s - Calaspargase pegol in adults with all
Servier Bioinnovation - A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05283720 - Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
AbbVie Inc. · Active, not recruiting · NCT03229200 - M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.